<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Sir William Dunn Sch of Pathology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AE2B32CB-0046-41BC-A835-00DC26997544"><gtr:id>AE2B32CB-0046-41BC-A835-00DC26997544</gtr:id><gtr:firstName>Shona</gtr:firstName><gtr:surname>Murphy</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400653"><gtr:id>21ECC6A6-9068-4D03-B5C0-626023C998E2</gtr:id><gtr:title>Gene type specific control of pol II transcription elongation</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400653</gtr:grantReference><gtr:abstractText>The genes contained in our chromosomes direct the production of all the components that the cells within our bodies need to survive and function correctly. To ensure that the appropriate products are made at the right time and in the right place the activity of our genes is regulated. Thus, some genes will be ?switched on? in some cells and ?switched off? in others or the activity finely tuned to make just the right amount of product. Our Cooperative Group of eight different research teams is studying different ways gene activity is regulated in a range of organisms including viruses, bacteria, yeast and man. The work of each group is complementary and every new discovery that each team makes contributes to the picture we have of the fundamental principles of gene control. The appearance of a product in the wrong cell or at the wrong time can result in diseases like cancer, cystic fibrosis and haemophilia. Our research into the control of the regulatory processes involved in decoding the information contained in different types of human genes will help to fully understand the underlying cause of such diseases. An understanding of the basic mechanisms of the control of expression of human genes is also necessary to devise effective drug or gene therapy strategies to combat disease caused by gene defects.</gtr:abstractText><gtr:technicalSummary>Dynamic phosphorylation of the unusual CTD of the large subunit of mammalian pol II, which comprises 52 repeats of a consensus heptapeptide, plays a key role in connecting RNA processing to transcription and controlling transcription elongation. For example, phosphorylation of the serine at position 2 (ser2) of the heptapeptide repeats by the positive elongation factor b (P-TEFb) can both facilitate interactions required for elongation of transcription of protein-coding templates and activate co-transcriptional RNA processing. However, the molecular mechanisms underlying P-TEFb function are not yet fully understood. We have recently shown that inhibition of phosphorylation by P-TEFb has little effect on transcription of the short, intron-less U2 gene but effectively blocks productive elongation of the longer, intron-containing b-actin gene. Since phosphorylation of ser2 by P-TEFb occurs during transcription of snRNA genes and is required for efficient 3? end formation of the transcripts, the basis for differential control of elongation is unclear. Insertion of an intron or an HIV Tar sequence downstream of an snRNA promoter causes readthrough of the RNA 3? end formation signal, the 3? box, possibly due to conversion of pol II to a more elongation competent form by P-TEFb. Thus, there appears to be a balance between the effect of P-TEFb function on RNA processing and elongation of transcription. We therefore propose to use several complementary approaches to identify the molecular interactions controlling elongation of transcription in different types of pol II-dependent genes.</gtr:technicalSummary><gtr:fund><gtr:end>2008-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>177832</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Center for Integrated Protein Science Munich (CIPSM)</gtr:department><gtr:description>CTD Serine7 phosphorylation</gtr:description><gtr:id>B6811E5D-0611-4B55-975F-049F217F1893</gtr:id><gtr:impact>S. Egloff, D. O'Reilly, R. Chapman, A. Taylor, K Tanzhaus, L. Pitts, D. Eick and S. Murphy. (2007) Serine 7 of the RNA polymerase II CTD is specifically required for snRNA gene expression. Science 318, 1777-1780.</gtr:impact><gtr:partnerContribution>We received reagents critical for our research.</gtr:partnerContribution><gtr:piContribution>We performed all of the analyses of expression of human snRNA genes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A87C4663-01F7-4E7F-B9DD-C603D383721A</gtr:id><gtr:impact>Biochemical Society Meeting

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C40F49C4-3179-4111-AA24-E19318DB9720</gtr:id><gtr:impact>RNA Society meeting

None</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>244168</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant (Connecting transcription of small nuclear RNA genes with RNA 3 end formation)</gtr:description><gtr:end>2009-12-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>8A7D45EA-24A9-4266-94B8-AC75AE9268AD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Several new drug resistant forms of the large subunit of RNA polymerase II (pol II) with a range of mutations in the carboxy-termina domain (CTD) were made.</gtr:description><gtr:id>C1A2D618-224A-4EF8-8501-353B65B7FB20</gtr:id><gtr:impact>We wwere able to determine that phosphorylation of a specific residue of the CTD is required for gene-type-specific expression of human snRNA genes. This was published in Science-18079403</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Pol II CTD mutants</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/17514F97-12E8-431A-994E-72D6FD178330"><gtr:id>17514F97-12E8-431A-994E-72D6FD178330</gtr:id><gtr:title>The integrator complex recognizes a new double mark on the RNA polymerase II carboxyl-terminal domain.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/72596BB1-0A1E-496C-B879-FD5163320876"><gtr:id>72596BB1-0A1E-496C-B879-FD5163320876</gtr:id><gtr:title>Updating the RNA polymerase CTD code: adding gene-specific layers.</gtr:title><gtr:parentPublicationTitle>Trends in genetics : TIG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-9525</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0D2C33CC-859E-454E-8841-451F5D1D248E"><gtr:id>0D2C33CC-859E-454E-8841-451F5D1D248E</gtr:id><gtr:title>The point of no return: The poly(A)-associated elongation checkpoint.</gtr:title><gtr:parentPublicationTitle>RNA biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0f93fc42c8aaef6d2aa9972d76d30517"><gtr:id>0f93fc42c8aaef6d2aa9972d76d30517</gtr:id><gtr:otherNames>Tellier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1547-6286</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/020F8F49-287C-43E0-A58F-D3BC7FDC6831"><gtr:id>020F8F49-287C-43E0-A58F-D3BC7FDC6831</gtr:id><gtr:title>The 7SK snRNP associates with the little elongation complex to promote snRNA gene expression.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8FDA1E9-B703-4A85-B216-30CCEDF6CA32"><gtr:id>B8FDA1E9-B703-4A85-B216-30CCEDF6CA32</gtr:id><gtr:title>P-TEFb goes viral.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/902c64ce38331eba7823e490547bc157"><gtr:id>902c64ce38331eba7823e490547bc157</gtr:id><gtr:otherNames>Zaborowska J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9468F5B1-E80D-462E-A69C-E72B9D169E11"><gtr:id>9468F5B1-E80D-462E-A69C-E72B9D169E11</gtr:id><gtr:title>CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II-transcribed genes.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b4cbf69133f60bc204ce37fbdc01ad50"><gtr:id>b4cbf69133f60bc204ce37fbdc01ad50</gtr:id><gtr:otherNames>Laitem C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D1C095A9-FE45-48A1-A890-B1A6A810680B"><gtr:id>D1C095A9-FE45-48A1-A890-B1A6A810680B</gtr:id><gtr:title>Chromatin structure is implicated in &amp;quot;late&amp;quot; elongation checkpoints on the U2 snRNA and beta-actin genes.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFD65C4C-899E-46F1-836C-69136FF4F77D"><gtr:id>FFD65C4C-899E-46F1-836C-69136FF4F77D</gtr:id><gtr:title>Cracking the RNA polymerase II CTD code.</gtr:title><gtr:parentPublicationTitle>Trends in genetics : TIG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0168-9525</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58ED055C-56CC-4B1F-B30C-5EC6A68822B2"><gtr:id>58ED055C-56CC-4B1F-B30C-5EC6A68822B2</gtr:id><gtr:title>Serine-7 of the RNA polymerase II CTD is specifically required for snRNA gene expression.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0406C0E8-0704-4225-9026-441536CF2D47"><gtr:id>0406C0E8-0704-4225-9026-441536CF2D47</gtr:id><gtr:title>Ser7 phosphorylation of the CTD recruits the RPAP2 Ser5 phosphatase to snRNA genes.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/647dbe625199830d78f55f081ef3938e"><gtr:id>647dbe625199830d78f55f081ef3938e</gtr:id><gtr:otherNames>Egloff S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400653</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>